Results 91 to 100 of about 310,703 (307)

Cardiology: hypertrophic cardiomyopathy [PDF]

Clinical Medicine, 2019
Hypertrophic cardiomyopathy (HCM) is defined by the presence of increased left ventricular (LV) wall thickness (for adults, >15 mm in one or more LV myocardial segments) that is not solely explained by abnormal loading conditions (eg hypertension).
openaire   +2 more sources

Prediction of sarcomere mutations in subclinical hypertrophic cardiomyopathy. [PDF]

, 2014
BACKGROUND: Sarcomere protein mutations in hypertrophic cardiomyopathy induce subtle cardiac structural changes before the development of left ventricular hypertrophy (LVH).
Bassett, P, Bluemke, DA, Canter, CE, Captur, G, Day, SM, Elliott, PM, Esteban, MT, Ferreira, VM, Finocchiaro, G, Ho, CY, Li, C, Lopes, LR, McKenna, WJ, Mohun, TJ, Moon, JC, Muthurangu, V, Patel, V, Seidman, CE, Sherrid, MV   +18 more
core   +1 more source

A contemporary simple risk score for prediction of severe acute kidney injury after heart transplantation

ESC Heart Failure, Volume 12, Issue 2, Page 1166-1175, April 2025.
A contemporary simple risk score for prediction of severe AKI after HT. Abstract Background The aim of this study was to develop a simple risk score to estimate severe acute kidney injury (AKI) risk based on a large contemporary heart transplantation (HT) cohort.
Shuangshuang Zhu, Weihua Qiao, Yixuan Wang, Ying Zhou, Yin Xu, Shijie Wang, Tian Xia, Guohua Wang, Si Chen, Jiawei Shi, Nianguo Dong   +10 more
wiley   +1 more source

The role of cardiac troponin T quantity and function in cardiac development and dilated cardiomyopathy [PDF]

, 2008
Background: Hypertrophic (HCM) and dilated (DCM) cardiomyopathies results from sarcomeric protein mutations, including cardiac troponin T (cTnT, TNNT2).
Ahmad, F, Banerjee, SK, Conner, DA, Huang, XN, Janczewski, AM, Keller, BB, Lage, ML, Mathier, MA, Moskowitz, IP, Perez-Atayde, AR, Rager, J, Saba, S, Seidman, CE, Seidman, JG, Shroff, SG, Smith, SH, Tinney, JP, Tobita, K   +17 more
core   +4 more sources

Metabolic abnormalities and reprogramming in cats with naturally occurring hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1256-1270, April 2025.
Abstract Background and aims The heart is a metabolic organ rich in mitochondria. The failing heart reprograms to utilize different energy substrates, which increase its oxygen consumption. These adaptive changes contribute to increased oxidative stress.
Qinghong Li, Max Homilius, Erin Achilles, Laura K. Massey, Victoria Convey, Åsa Ohlsson, Ingrid Ljungvall, Jens Häggström, Brittany Vester Boler, Pascal Steiner, Sharlene Day, Calum A. MacRae, Mark A. Oyama   +12 more
wiley   +1 more source

Evidence of Declining Mortality Trends for Hypertrophic Cardiomyopathy in the United States and the Impact of the COVID‐19 Pandemic

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Dedicated hypertrophic cardiomyopathy (HCM) center cohorts have reported reductions in HCM‐related deaths, likely due to the introduction of contemporary treatments.
Ahmed Sayed, Barry J. Maron, Ethan J. Rowin, Martin S. Maron   +3 more
doaj   +1 more source

Identification of a novel titin-cap/telethonin mutation in a Portuguese family with hypertrophic cardiomyopathy

Revista Portuguesa de Cardiologia, 2020
Introduction and objectives: Hypertrophic cardiomyopathy (HCM) is a genetically and phenotypically heterogeneous disease; there is still a large proportion of patients with no identified disease-causing mutation.
Alexandra Toste, Andreas Perrot, Cemil Özcelik, Nuno Cardim   +3 more
doaj   +1 more source

Automatic Segmentation and Disease Classification Using Cardiac Cine MR Images

, 2017
Segmentation of the heart in cardiac cine MR is clinically used to quantify cardiac function. We propose a fully automatic method for segmentation and disease classification using cardiac cine MR images.
Isgum, Ivana, Leiner, Tim, Viergever, Max A., Wolterink, Jelmer M.   +3 more
core   +2 more sources

Patient and Disease-Specific Induced Pluripotent Stem Cells for Discovery of Personalized Cardiovascular Drugs and Therapeutics. [PDF]

, 2020
Human induced pluripotent stem cells (iPSCs) have emerged as an effective platform for regenerative therapy, disease modeling, and drug discovery.
Chandy, Mark, Paik, David T, Wu, Joseph C   +2 more
core  

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source